Imiquimod [99011-02-6]

Imprimir

Referência 280414-100mg

Tamanho : 100mg

Contactar o distribuidor local :

Telefone : +1 850 650 7790

Marca : US Biological

Solicitar mais informações

Contactar o distribuidor local :

Telefone : +1 850 650 7790

280414 Imiquimod

Grade

Highly Purified

Shipping Temp

Storage Temp

4°C

Cell-permeable. Topical immune response modifier that displays anti-angiogenic, anti-viral and anti-inflammatory properties. Up-regulates IL-18 and down-regulates MMP-9 through recognition of Toll-like receptor 7 (TLR7) and subsequent activation of MyD88-dependent pathway. Stimulates proinflammatory cytokine production interferon-alpha (IFN-alpha), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) and activates NF-kappaB. Caspase-3 activator that directly induces procaspase-3 cleavage. Anti-cancer compound. Apoptosis inducer. Antiproliferative, independent of immune system activation or function. Approved treatment for external genital warts caused by human papillomavirus infection.

Synonyms:
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; S26308; R-837

CAS Number:
99011-02-6

Molecular Weight:
240.30

Molecular Formula:
C14H16N4

Appearance:
Supplied as a white to off-white powder.

Purity:
≥98%

Solubility:
DMSO or dimethylformamide. Insoluble in ethanol. Slightly soluble in water.

Storage and Stability:
Store at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Applications

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. Toxicity and Hazards: All products should be handled by qualified personnel only, trained in laboratory procedures.

Form

White crystalline powder

Purity

≥98%

References

●Imiquimod applied topically: a novel immune response modifier and new class of drug: R.L. Miller, et al.; Int. J. Immunopharmacol. 21, 1 (1999)|●A review of the applications of imiquimod: a novel immune response modifier: T.A. Syed, et al.; Exp. Opin. Pharmacother. 2, 877 (2001)|●Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002)|●Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod: M. Schon, et al.; J. Natl. Cancer Inst. 95, 1138 (2003)|●Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7: J. Lee, et al.; PNAS 100, 6646 (2003) |●In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases: C. Hesling, et al.; Br. J. Dermatol. 150, 761 (2004)|●Imiquimod as an antiangiogenic agent: V.W. Li, et al.; J. Drugs Dermatol. 4, 708 (2005)|●Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis: S. Majewski, et al.; Int. J. Dermatol. 44, 14 (2005)|●The antitumoral mode of action of imiquimod and other imidazoquinolines: M. Schon & M.P. Schon; Curr. Med. Chem. 14, 681 (2007)|●The pharmacology of endosomal TLR agonists in viral disease: D.R. Averett, et al.; Biochem. Soc. Trans. 35, 1468 (2007)

Você também pode estar interessado nos seguintes produtos:

Referência

Descrição

Cond.

Price Bef. VAT

331-20080-1

Imiquimod hydrochloride

100mg

331-11153-1

Imiquimod

100mg

462984-25ml

Pristane [1921-70-6]

25ml